Evidence map›Paper›PMID 40249442›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Enhancing Biosafety Protocols in Laboratories Conducting Research on the Yellow Fever Virus.

Alice Gomes Fernandes

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Alice Gomes FernandesNuclear Magnetic Resonance (NMR) Platform, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Manguinhos, Rio de Janeiro, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

All biological samples are potentially infectious, requiring vaccination and protective equipment for laboratory personnel. The risk classification of pathogenic microorganisms, including the yellow fever virus (YFV), is based on potential risks to individuals, communities, and the environment. Countries have their own classification systems, with Brazil previously following global standards until 1995. YFV is classified as a Risk Group 3 pathogen by the WHO, necessitating handling in Biosafety Level 3 (BSL3) laboratories. Personnel must be vaccinated against YFV at least 10 days prior to contact, as there have been cases of occupationally acquired infections among healthcare and laboratory workers.

Indexed as

Containment of BiohazardsLaboratoriesYellow FeverYellow fever virusBrazilHumansYellow Fever VaccineYellow Fever VaccineLaboratory safetyPathogen risk classificationYellow fever firusYellow fever vaccine

Identifiers

PMID40249442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.